Description  Claims  Cited references 

WO2013074916A   [0010] 
US4683195A   [0015] 
WO2012058458A   [0026] 
US6010613A   [0039] 
WO2004083379A   [0039] 
US6352694B   [0041] 
US6534055B   [0041] 
US6905680B   [0041] 
US6692964B   [0041] 
US5858358A   [0041] 
US6887466B   [0041] 
US6905681B   [0041] 
US7144575B   [0041] 
US7067318B   [0041] 
US7172869B   [0041] 
US7232566B   [0041] 
US7175843B   [0041] 
US5883223A   [0041] 
US6905874B   [0041] 
US6797514B   [0041] 
US6867041B   [0041] 
US20060121005   [0041] 
WO2006097854A   [0062] 
US2013051783W   [0065] 
WO2012138927A   [0066] 
WO9424277A   [0073] 
US6642043B   [0073] 
WO201370718A   [0105] 

Blood   [0009] 
Molecular Therapy   [0011] 
Current Protocols in Molecular Biology   [0015] 
Molecular Cloning: A Laboratory Manual   [0015] 
Oligonucleotide Synthesis   [0015] 
Nucleic Acid Hybridization   [0015] 
Transcription And Translation   [0015] 
Culture Of Animal Cells   [0015] 
Immobilized Cells And Enzymes   [0015] 
A Practical Guide To Molecular Cloning   [0015] 
the series, Methods In ENZYMOLOGY   [0015] 
Gene Expression Technology   [0015] 
Gene Transfer Vectors For Mammalian Cells   [0015] 
Immunochemical Methods In Cell And Molecular Biology   [0015] 
Handbook Of Experimental Immunology   [0015] 
Manipulating the Mouse Embryo   [0015] 
J. of General Virology   [0037] 
J. of Gen. Virology   [0037] 
Mol. And. Cell. Biology   [0037] 
RNA   [0037] 
Basic and Clinical Immunology   [0040] 
Cell   [0057] 
Immun.   [0057] 
Citrr. Opin. mm n.   [0057] 
Retroviridae: The viruses and their replication   [0079] 
Resistance to cytarabine and gemcitabine and in vitro selection of transduced cells after retroviral expression of cytidine deaminase in human hematopoietic progenitor cells.   [0104] 
Breaking the code of DNA binding specificity of TAL-type III effectors.   [0104] 
Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers.   [0104] 
Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease.   [0104] 
Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting.   [0104] 
Targeting DNA double-strand breaks with TAL effector nucleases.   [0104] 
Multiplex genome engineering using CRISPR/Cas systems.   [0104] 
DNA end-joining: from yeast to man.   [0104] 
CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III.   [0104] 
Structural basis for sequence-specific recognition of DNA by TAL effectors.   [0104] 
The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA.   [0104] 
Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria.   [0104] 
Transcriptional activators of human genes with programmable DNA-specificity.   [0104] 
Genetic modification of mouse bone marrow by lentiviral vector-mediated delivery of hypoxanthine-Guanine phosphoribosyltransferase short hairpin RNA confers chemoprotection against 6-thioguanine cytotoxicity   [0104] 
Heritable gene targeting in zebrafish using customized TALENs.   [0104] 
Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9.   [0104] 
A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.   [0104] 
Engineering human T cells for resistance to methotrexate and mycophenolate mofetil as an in vivo cell selection strategy.   [0104] 
Expression of human glutathione S-transferase P1 confers resistance to benzo[a]pyrene or benzo[a]pyrene-7,8-dihydrodiol mutagenesis, macromolecular alkylation and formation of stable N2-Gua-BPDE adducts in stably transfected V79MZ cells co-expressing hCYP1A1.   [0104] 
Complete genome sequence of Burkholderia rhizoxinica, an Endosymbiont of Rhizopus microsporus.   [0104] 
Rapid and highly efficient construction of TALE-based transcriptional regulators and nucleases for genome modification.   [0104] 
Modularly assembled designer TAL effector nucleases for targeted gene knockout and gene replacement in eukaryotes.   [0104] 
Yeast Mre11 and Rad1 proteins define a Ku-independent mechanism to repair double-strand breaks lacking overlapping end sequences.   [0104] 
Targeted transcriptional repression using a chimeric TALE-SRDX repressor protein.   [0104] 
De novo-engineered transcription activator-like effector (TALE) hybrid nuclease with novel DNA binding specificity creates double-strand breaks.   [0104] 
The crystal structure of TAL effector PthXo1 bound to its DNA target.   [0104] 
RNA-guided human genome engineering via Cas9.   [0104] 
Retroviral-mediated expression of the P140A, but not P140A/G156A, mutant form of O6-methylguanine DNA methyltransferase protects hematopoietic cells against O6-benzylguanine sensitization to chloroethylnitrosourea treatment.   [0104] 
LAIR-1, a novel inhibitory receptor expressed on human mononuclear leukocytes.   [0104] 
A TALE nuclease architecture for efficient genome editing.   [0104] 
Regulation of selected genome loci using de novo-engineered transcription activator-like effector (TALE)-type transcription factors.   [0104] 
A simple cipher governs DNA recognition by TAL effectors.   [0104] 
A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity.   [0104] 
Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes.   [0104] 
Engineered resistance to camptothecin and antifolates by retroviral coexpression of tyrosyl DNA phosphodiesterase-I and thymidylate synthase.   [0104] 
Treating cancer with genetically engineered T cells.   [0104] 
Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF.   [0104] 
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes.   [0104] 
Targeted gene disruption in somatic zebrafish cells using engineered TALENs.   [0104] 
Lentiviral vector conferring resistance to mycophenolate mofetil and sensitivity to ganciclovir for in vivo T-cell selection.   [0104] 
Dihydrofolate reductase as a therapeutic target.   [0104] 
CRISPR-mediated Adaptive Immune Systems in Bacteria and Archaea   [0104] 
Homing endonuclease structure and function.   [0104] 
Drug-selected co-expression of P-glycoprotein and gp91 in vivo from an MDR1-bicistronic retrovirus vector Ha-MDR-IRES-gp91.   [0104] 
Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene.   [0104] 
Knockout rats generated by embryo microinjection of TALENs.   [0104] 
Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation.   [0104] 
Assembly of designer TAL effectors by Golden Gate cloning.   [0104] 
Ex vivo selection and expansion of cells based on expression of a mutated inosine monophosphate dehydrogenase 2 after HIV vector transduction: effects on lymphocytes, monocytes, and CD34+ stem cells.   [0104] 
Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription.   [0104] 
Siglec-9, a novel sialic acid binding member of the immunoglobulin superfamily expressed broadly on human blood leukocytes.   [0104] 
In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning.   [0104]